# FDA recall D-1499-2014

> **Teva Pharmaceuticals USA** · Class II · drug recall initiated 2014-04-01.

## Product

triple therapy, LANSOPRAZOLE DR Capsules USP 30mg, CLARITHROMYCIN Tablets USP 500mg, AMOXICILLIN Capsules USP 500mg, 8 count Blister Pack  Lansoprazole DR Capsules USP &  Clarithromycin Tablets USP, MANUFACTURED Israel for Teva Pharmaceuticals USA, Sellersville, PA 18960, Amoxicillin Capsules USP manufactured in Canada, for  Teva Pharmaceuticals USA, Sellersville, PA 18960. NDC# 0093-8055-78

## Reason for recall

Failed Impurities/Degradation Specifications: This recall is due to out of specification for impurities test results obtained during stability testing for Lansoprazole.

## Distribution

Nationwide

## Key facts

- **Recall number:** D-1499-2014
- **Recalling firm:** Teva Pharmaceuticals USA
- **Classification:** Class II
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2014-04-01
- **Report date:** 2014-08-06
- **Termination date:** 2014-11-20

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Horsham, PA, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-1499-2014

## Citation

> AI Analytics. FDA recall D-1499-2014. Retrieved 2026-06-23 from https://api.ai-analytics.org/recall/D-1499-2014. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*